Chronic inhibition of the high-affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra

Free Radical Biology and Medicine

Volumn 23, Issue 1, 1997, Pages 1-7

  Romero Ramos, Marina ^a   Rodríguez Gómez, Jose A ^a   Venero, Jose L ^a   Cano, Josefina ^a   Machado, Alberto ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Aging; Free radicals; Nomifensine; Oxidative stress; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; NOMIFENSINE; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

AGED; AGING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOPAMINE UPTAKE; ENZYME INACTIVATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ASSAY; RAT; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; AGING; ANIMALS; BLOTTING, WESTERN; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FREE RADICALS; MALE; NOMIFENSINE; OXIDATIVE STRESS; PROTEINS; RATS; RATS, WISTAR; SELEGILINE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 0030960225     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(96)00405-4     Document Type: Article

References (36)

1. de la Cruz C. P., Revilla E., Venero J. L., Ayala A., Cano J., Machado A. Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rats. Free Radic. Biol. Med. 20:1995;53-61.
2. Harman D. The aging process. Proc. Natl. Acad. Sci. USA. 78:1981;7124-7128.
3. Knoll J. The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases. J. Neural. Transm. Suppl. 40:1993;69-91.
4. Effect of tocopherol deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328:1993;176-183.
5. Birkmayer W., Knoll J., Riederer P., Hars V., Marton J. Improvement of life expectancy due to L-deprenyl addition to madopar treatment in Parkinson's disease. J. Neural. Transm. 64:1985;113-127.
6. Knoll J. Nigrostriatal dopaminergic activity (-)deprenyl treatment and longevity. Adv. Neurol. 53:1990;425-429.
7. Knoll J., Toth V., Kummmert M., Sugar J. (-)Deprenyl and parafluorodeprenyl treatment prevents age-related pigment changes in substantia nigra. A TV-image analysis of neuromelanin. Mech. Ageing Dev. 68:1992;157-163.
8. Cohen G., Spina M. B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26:1989;689-690.
9. Gelowitz D. L., Richarson J. S., Wishart T. B., Yu P. H., Lai C. T. Chronic L-deprnyl or L-amphetamine; equal cognitive enhancement, unequal MAO inhibition. Pharmacol. Biochem. Behav. 47:1994;41-45.
10. Murphy M. P., Wu P. H., Milgram N. M., Ivy G. O. Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat. Neurochem. Res. 18:1993;1299-1304.
11. Carrillo M. C., Kitani K., Kanai S., Sato Y., Miyasaka K., Ivy G. O. The effect of a long-term (6 months) treatment with (-)Deprenyl on antioxidant enzyme activities in selective brain regions in old female Fisher-344 rats. Biochem. Pharmacol. 47:1994;1333-1338.
12. Ahn B., Rhee S. G., Stadtman E. R. Use of fluorescein hydrazide and fluorescein thiosemicarbazide reagents for the fluorometric determination of protein carbonyl groups and for the detection of oxidized protein on polyacrylamide gels. Anal. Biochem. 161:1987;245-257.
13. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 2nd:1986;Academic Press, San Diego.
14. Castaño A., Cano J., Machado A. Low selenium diet affects monoamine turnover in substantia nigra and striatum. J. Neurochem. 61:1993;1302-1307.
15. 2O and adsorption of (3H)tyrosine by charcoal. Life Sci. 39:1986;2185-2189.
16. 4. Nature. 227:1970;680-685.
17. Lenz A. G., Costabel U., Shaltiel S., Levine R. L. Determination of carbonyl groups in oxidatively modified proteins by reduction with tritiated sodium boroydride. Anal. Biochem. 177:1989;419-425.
18. Lowry O. H., Rosebourgh N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
19. Firestone J. A., Gerhardt G. A., De Bernardes S. F., Makelvy J. F., Browning M. D. Actions of A-75200 a novel catecholamine uptake inhibitor on norepinephrine uptake and release from bovine adrenal chromaffin cells. J. Pharmacol. Exp. Ther. 264:1993;1206-1210.
20. 3H]Dopamine from rat striatal slices. Biochem. Pharmacol. 31:1982;2961-2968.
21. Chamb G., Renaud B. Increased tyrosine hydroxylase activity in central adrenaline neurons after reserpine treatment. Eur. J. Pharmacol. 92:1983;243-248.
22. Vrana S. L., Vrana K. E., Koves T. R., Smith J. E., Dworkin S. I. Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. J. Neurochem. 61:1993;2262-2268.
23. Nielsen J. A., Chapin D. S., Moore K. E. Differential effects of d-amphetamine, β -phenyethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolism into cerebroventricular perfusates of rats. Life Sci. 33:1983;1899-1907.
24. Warning S. E., Shipley S. D., Leedham J. A., Hartley M. L., Hadberg G. M., Pennfether J. N. The influence of neuronal uptake upon the relative potencies of agonist acting at prejunctional alpha-2-adrenoceptors in the rat isolated vas deferens. Arch. Int. Pharmacodyn. Ther. 259:1982;14-30.
25. Vanhatalo S., Soiml S. Pharmacological characterization of serotonine synthesis and uptake suggest a false transmitter role for serotonine in the pituitary intermediate lobe. Neurosci. Res. 21:1994;143-149.
26. Cesura A. M., Pletscher A. The new generation of monoamine oxidase inhibitors. Prog. Drug. Res. 38:1992;171-297.
27. Stadman E. R. Oxidation of proteins by mixed-function oxidation system: Implication in protein turnover: Aging and neurotrophil function. Trends Biochem. Sci. 11:1986;11-12.
28. Spina M. B., Cohen G. Dopamine turnover and glutathione oxidation: Implications for Parkinson Disease. Proc. Natl. Acad. Sci. USA. 86:1989;1389-1400.
29. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1616.
30. Gerlach M., Ben-Shachar D., Riederer P., Youdim M. B. H. Altered brain metabolism of iron as a cause of neurodegenerative disease? J. Neurochem. 63:1994;793-807.
31. Graham D. G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14:1978;633-634.
32. Cohen G. Oxy-radical toxicityin cathecolamines neurons. Neurotoxicology. 5:1984;77-82.
33. Graham D. G. Catecholamine toxicity: A proposal for the molecular pathogenesis of magnese neurotoxicity and Parkinson's Disease. Neurotoxicology. 5:1884;83-96.
34. 3H]Dopamine: Impact of ascorbic acid and glutathione. J. Neurochem. 63:1994;1126-1132.
35. Simonian N. A., Coyle J. T. Oxidative stress in neurodegenerative disease. Annu. Rev. Pharmacol. Toxicol. 36:1996;83-106.
36. Rudorfer M. V., Potter W. Z. Antidepressants. A comparative review of the clinical pharmacology and therapeutic use of the "newer" versus the "older" drugs. Drugs. 37:1989;713-738.